The Find It Early Act requires health coverage with no cost-sharing for additional breast cancer screening and diagnostic imaging for people judged to be at increased risk or who a clinician identifies as needing extra imaging. It covers a wide range of technologies — 2D/3D mammography, ultrasound, MRI, molecular breast imaging, contrast‑enhanced mammography and other modalities — and ties frequency to National Comprehensive Cancer Network (NCCN) guidance and applicable American College of Radiology (ACR) criteria.
The bill applies across the major federal and private systems: it amends the Public Health Service Act/ACA rules affecting group and individual plans (including grandfathered plans), adds parallel ERISA and Internal Revenue Code provisions for employer plans, expands Medicare coverage beyond USPSTF benchmarks, mandates Medicaid coverage and no cost‑sharing (with a defined state implementation window), and eliminates cost‑sharing under TRICARE and VA care. The objective is to lower financial barriers for higher‑risk patients; the tradeoffs are increased imaging utilization, fiscal impacts for payers and federal programs, and implementation choices about which clinical criteria providers must follow.
At a Glance
What It Does
Requires no cost-sharing for expanded breast cancer screening and diagnostic imaging for individuals identified as at increased risk or when a clinician determines extra imaging is needed. It specifies covered modalities and defers frequency to NCCN guidelines and ACR appropriateness criteria.
Who It Affects
Applies to insured populations (group and individual plans, including grandfathered plans), self‑insured ERISA plans, Medicare beneficiaries (traditional and Medicare Advantage), Medicaid enrollees, TRICARE beneficiaries, and veterans receiving VA care. Radiology providers and imaging centers will see changes in demand and billing rules.
Why It Matters
Shifts financial responsibility away from patients for additional screening tied to risk, potentially increasing early detection for subgroups under‑served by standard screening guidance. It expands preventive coverage beyond USPSTF recommendations, creates administrative obligations for payers across programs, and raises near‑term budget and capacity questions for payers and health systems.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a uniform, cross‑program rule: people at higher risk for breast cancer — as defined by the most recent applicable ACR Appropriateness Criteria or NCCN guidelines, and people with heterogeneously or extremely dense breasts under the BI‑RADS system — must receive screening and diagnostic breast imaging without patient cost‑sharing. It lists covered technologies explicitly (2D and 3D mammography, breast ultrasound, breast MRI, molecular breast imaging, contrast‑enhanced mammography) and leaves room for other technologies when those same guidelines recognize them.
Where a patient is not automatically in the higher‑risk group, the bill lets a treating clinician determine that additional imaging is necessary based on factors such as age, race, ethnicity, personal or family medical history, or other provider‑assessed risk. The bill requires payers to follow NCCN for how often to authorize such imaging; that frequency control is the primary utilization management anchor in the text.Implementation is surgical: the measure amends multiple statutes rather than creating a single new program.
For private coverage it adds a new section to the Public Health Service Act (affecting ACA‑regulated plans) and parallel provisions to ERISA and the Internal Revenue Code so self‑insured employer plans and tax‑qualified plans are captured. It specifically applies to grandfathered plans for plan years starting on or after January 1, 2026.
For federal programs, it amends Medicare’s statutory preventive services language to add the ACR/NCCN pathway beyond USPSTF recommendations, requires Medicare Advantage plans to waive cost‑sharing for the same services, adds the coverage and no cost‑sharing requirement to Medicaid (with special language preventing benchmark coverage from excluding these services), and creates analogous entitlements and copayment prohibitions for TRICARE and VA health care. The effective date for most provisions is January 1, 2026, and the bill contains a delayed compliance mechanism for Medicaid when state legislation is required to conform.
The Five Things You Need to Know
Effective date: most provisions take effect January 1, 2026, and apply to plan years beginning on or after that date.
Clinical authorities: the bill uses the most recent applicable American College of Radiology (ACR) Appropriateness Criteria and National Comprehensive Cancer Network (NCCN) guidelines to define increased risk and acceptable imaging choices and to set frequency.
Modalities covered: explicitly lists 2D/3D mammography, breast ultrasound, breast MRI, molecular breast imaging, and contrast‑enhanced mammography, and permits other guideline‑recognized technologies.
Medicare change: amends Medicare’s preventive services eligibility so coverage without cost‑sharing is available when ACR/NCCN criteria (not just USPSTF recommendations) indicate increased risk or clinician‑directed need; Medicare Advantage is required to mirror the no‑cost‑sharing rule.
Medicaid and benchmarks: prevents states from offering benchmark or benchmark‑equivalent coverage that omits these imaging services for eligible beneficiaries and includes a statutory transition window if state law change is necessary.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the statute the "Find It Early Act." This is the organizational anchor; it has no programmatic effect but identifies the package for statutory placement and cross‑references elsewhere in enacted text.
No cost‑sharing for risk‑based additional imaging in ACA‑regulated plans
Adds a new preventive‑coverage requirement to the Public Health Service Act that applies to group and individual plans regulated under title XXVII. The provision requires plans to cover, without cost‑sharing, the listed breast imaging modalities for people at increased risk as determined by ACR/NCCN or who have heterogeneously/extremely dense breasts per BI‑RADS, and also for patients a clinician determines need extra imaging for specified factors. The provision ties frequency to NCCN guidance, creating an external clinical yardstick payers must use when determining allowable intervals.
Parallel obligation for self‑insured and employer plans
Inserts an equivalent statutory requirement into ERISA so self‑insured employer plans are subject to the same no‑cost‑sharing rule. This is crucial because many large employers are self‑insured and otherwise outside state insurance mandates. The practical effect is that plan sponsors and third‑party administrators must update benefit designs and member communications to reflect covered modalities and the NCCN frequency standard.
Tax code cross‑reference to ensure consistency for group plans
Adds a new IRC section mirroring the coverage requirement for group health plans. The IRC insertion is primarily a codified cross‑reference to minimize discrepancies between tax‑qualified plan rules and ERISA/PHSA mandates; operationally it reinforces that employer‑sponsored plans’ tax status is not a loophole to avoid the coverage requirement.
Medicare coverage beyond USPSTF and MA plan cost‑sharing prohibition
Modifies Medicare’s statutory definition of covered preventive/screening services to add imaging authorized by ACR/NCCN for individuals at increased risk or where a clinician identifies need, and requires Medicare Advantage plans to waive cost‑sharing for those same services. This expands Medicare coverage authority beyond the traditional USPSTF‑only pathway and compels MA plans to align benefit design accordingly; contractors and CMS must update benefit guidance and claims processing rules.
Mandatory Medicaid coverage and no patient cost‑sharing; benchmark rule
Adds the imaging services into mandatory Medicaid benefits and prohibits cost‑sharing for them. It also bars states from using benchmark or benchmark‑equivalent packages that exclude these services, and provides a delayed compliance window when state legislative action is required. Practically, states must fold the modalities and NCCN frequency standard into their fee‑for‑service and managed care benefit packages and adjust contracts and budgets accordingly.
Entitlement and cost‑sharing elimination for uniformed service beneficiaries
Directs the Defense Department to cover listed breast imaging for eligible TRICARE beneficiaries and removes cost‑sharing for TRICARE Prime, Select, and contracted plans when beneficiaries meet the bill’s risk or provider‑determined criteria. The change requires the military health system to update TRICARE benefit guides, encounter coding and authorization rules, and may affect DoD budget lines supporting care and purchased care contracts.
VA coverage and prohibition on copayments for veterans
Creates a new VA statutory entitlement for veterans meeting the risk or clinician‑determined thresholds and bars copayments for those services, regardless of enrollment in VA annual patient enrollment. The VA must integrate the ACR/NCCN criteria into its clinical policy and ensure capacity to provide covered imaging without charging copays.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People at increased risk for breast cancer — patients identified by ACR/NCCN criteria or with BI‑RADS dense breasts will no longer face co‑pays or deductibles for the additional imaging the bill targets, reducing a direct financial barrier to risk‑tailored screening.
- Clinicians who manage high‑risk patients — providers gain clearer, payer‑enforceable coverage for recommending additional imaging, removing a frequent friction point when ordering advanced or more frequent studies.
- Veterans and TRICARE beneficiaries — the bill removes copayments in VA and TRICARE systems, directly lowering out‑of‑pocket costs for uniformed service members, veterans, and their families.
- Radiology and breast imaging centers — reduced patient cost barriers are likely to increase appropriate referrals and imaging volume for modalities currently limited by patient cost exposure.
- Low‑income Medicaid enrollees at risk — mandatory Medicaid coverage and the prohibition on cost‑sharing makes additional imaging financially accessible to beneficiaries who previously might have deferred care.
Who Bears the Cost
- Private insurers and self‑insured employers — must absorb the patient cost‑sharing previously collected, adjust benefit design, and potentially pay for more frequent or higher‑cost imaging.
- Federal programs and budgets (Medicare, Medicaid, DoD, VA) — will incur additional service utilization and associated payments; Medicaid also faces state budget impacts and potential need for legislative adjustments.
- States — must amend benchmark plans and managed‑care contracts, with potential fiscal pressure for state budgets and administrative costs for plan changes.
- Plan sponsors and TPA administrators — operational costs for benefit updates, revised prior authorization/claims systems, and member communications increase, particularly for large self‑insured employers.
- Health systems in capacity‑strained markets — increased demand for advanced imaging may require investment in equipment, staffing, or referral management, shifting costs to facilities or leading to scheduling backlogs.
Key Issues
The Core Tension
The bill confronts a simple but sharp dilemma: remove financial barriers so higher‑risk people can get more screening and potentially detect cancers earlier, versus the likelihood that broader, clinician‑driven access will raise utilization, produce more false positives and downstream procedures, and shift significant costs onto insurers, federal programs, and state budgets — with no new mechanism in the bill to manage utilization, reimbursement, or capacity.
The bill trades patient cost reductions for increased payer exposure to imaging utilization. Using NCCN and ACR criteria and BI‑RADS to define eligibility centralizes clinical authority in specialty guidance that evolves; payers must keep benefit rules aligned with the latest updates or face coverage disputes.
The provider‑decided pathway (clinician determines extra imaging based on age, race, ethnicity, family history, etc.) introduces variability in utilization: while it preserves clinical judgment where guideline categories don’t fit, it also creates potential for inconsistent application and disputes over medical necessity between providers and payers.
Implementation will be administratively complex. The measure stitches identical language into multiple statutory frameworks (PHSA, ERISA, IRC, Medicare, Medicaid, TRICARE, VA), which reduces carve‑outs but requires separate regulatory and contract changes across agencies and states.
Medicaid’s benchmark restriction and the state‑legislation delay help, but states still face actuarial and procurement work to add modalities and NCCN frequency standards to managed care contracts. On the clinical side, expanded imaging may increase false positives and downstream diagnostic procedures; the bill does not adjust reimbursement incentives, prior authorization protocols, or provider capacity planning to address those consequences.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.